Old boatRegenxbio $RGNX
Grew revenue 105% in FY2025 to $170 million, operating margin -94.6% against a -15.8% median for biological products, (no diagnostic substances), equity 22.7% of assets.
Last filing10-Q, 5 Nov 2026
Edgarette’s full reading · exposure, experience, soundness, credibility, range
🫧 Edgar looked up REGENXBIO Inc. ($RGNX). Last filing: 10-Q, 2026-11-05. 14 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $170.4M (FY2025). Experience: revenue up 104.5% on the year, down 22.4% a year over 4 years; operating margin -94.6%, up from -280.0%. Soundness: equity 22.7% of assets, return on equity -188.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $156.7M and $461.0M next year (method v4.1: its own 3-year record of growth weighed at 40% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $119.3M to $612.4M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -94.6% against a -15.8% median; growth 104.5% against 21.4%.
Read from its own SEC filings · nothing written, nothing inferred
Speed and cash · fiscal 2025
Both views must agree for a label · a description, not advice.
| Cash flow (op · inv · fin · free) | −$124M · −$16M · $117M · −$126M |
| Investment book (cash · short · long) | $34M · $196M · $11M · current ratio 2.38 · unrealized $0M |
| Revenue swing · equity of assets | 50.5% · 22.7% |
Regenxbio is growing faster than its size class, with revenue that swings more. Its own audited SEC figures.
The figures, as filed
| Fiscal year end | 2025-12-31 |
| Revenue | $170M |
| Revenue, on the year | 104.5% |
| Revenue, a year over the record | −22.4% |
| Operating margin | −94.6% |
| Operating margin, prior year | −280.0% |
| Net margin | −113.8% |
| Research and development | $228M · 133.9% of revenue |
| Total debt | — |
| Equity of assets | 22.7% |
| Return on equity | −188.7% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-3.76 |
| Book value per share | $1.99 |
| Revenue per share | $3.30 |
| Shares outstanding | 51,573,000 |
| Audited years read | 5 |
Peers: the median of 31 filers with $50M+ revenue in biological products, (no diagnostic substances).
Classic signals · fiscal 2025Altman Z″ -7.82 distress zone 1968Piotroski F 4 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals -15.2% earnings backed by cash 1996DuPont ROE -107% = margin -113.8% × turns 0.37 × leverage 2.54
What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →
Health HarborRegenxbio sails as: Old boat
Health watch · 12 monthsDirector or officer change ×2
Sailing speed follows growth: 14.8% a year crosses the harbor in 36 seconds.
🌊 Visit the Bay →- operating cash flow was negative
- operating loss: a margin of -94.6% in FY2025
- revenue is hard to predict: its 80% range is ±49%
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 10-Q · 2026-11-05
- 8-K · 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
- 8-K · 2026-10-16 · 5.02 Departure or Election of Directors; Appointment of Officers
- 8-K · 2026-09-23 · 1.01 Entry into a Material Definitive Agreement
- 8-K · 2026-08-25 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits
- 8-K · 2026-08-24 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.
Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·